MELBOURNE, Australia and SAN FRANCISCO, March 02, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ...

Currently no disease-modifying or neuroprotective treatments exist for MSA, nor are there effective medications to treat the cerebellar ataxia in MSA-C or the parkinsonian features in MSA-P. Physical ...

Emrusolmin is expected to improve symptoms of MSA by targeting alpha synuclein oligomers. The Food and Drug Administration (FDA) has granted Fast Track designation to emrusolmin (TEV-56286) for the ...

Phase 1b data on Lu AF28996, an investigational treatment for people with advanced Parkinson’s disease, to be presented at ...

MELBOURNE, Australia and SAN FRANCISCO, April 10, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying ...

– Company is advancing ATH434 in late-stage clinical development for Multiple System Atrophy, a rapidly progressive neurodegenerative disease with no approved therapies – MSA is a progressive ...

The Food and Drug Administration (FDA) has granted Fast Track designation to verdiperstat (BVH-3241; Biohaven) for the treatment of multiple system atrophy. The Food and Drug Administration (FDA) has ...

Multiple system atrophy is a rare, progressive neurodegenerative condition for which there is currently no cure. Multiple system atrophy (MSA) is a progressive neurodegenerative disorder with an ...

– Company is advancing ATH434 in late-stage clinical development for Multiple System Atrophy, a rapidly progressive neurodegenerative disease with no approved therapies – MELBOURNE, Australia and SAN ...